HU14.18-IL2 Uses, Dosage, Side Effects and more
HU14.18-IL2 is under investigation in clinical trial NCT01334515 (Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma).
| Attribute | Details |
|---|---|
| Trade Name | HU14.18-IL2 |
| Generic | Lorukafusp alfa |
| Lorukafusp alfa Other Names | EMD 273063, HU14.18-IL2, Lorukafusp alfa |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
